GO:2001027 negative regulation of endothelial cell chemotaxis: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001027 describes any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell chemotaxis, the directed migration of endothelial cells along a chemical gradient.
• Endothelial cell chemotaxis is driven by chemoattractants such as VEGF and sphingosine-1-phosphate (S1P), and its negative regulation involves braking signaling nodes including Rho kinase, G(ialpha2)-linked pathways and Fes kinase.
• Gefitinib inhibits endothelial cell chemotaxis toward FGF-2 and this inhibition associates with downregulation of Fes activity, linking a clinically used tyrosine kinase inhibitor to negative regulation of endothelial chemotaxis.
• Dysregulated endothelial chemotaxis contributes to pathological angiogenesis, inflammatory barrier dysfunction and aberrant vascular remodeling, making its negative regulation a therapeutic target.
• CRISPR knockout, point-mutation, knock-in and overexpression cell models allow causal testing of candidate brakes on endothelial chemotaxis, while CRISPR library screening can nominate new negative regulators at scale.
• QuickGO defines GO:2001027 as a biological process with no listed synonyms, and it is best studied with migration assays, phospho-signaling readouts and transcriptomic or proteomic profiling.
Description
GO:2001027, negative regulation of endothelial cell chemotaxis, is a Gene Ontology biological process term that captures any mechanism which stops, prevents or reduces the directed migration of endothelial cells toward a chemical cue. Endothelial chemotaxis is central to angiogenesis, vascular repair and barrier homeostasis, and it is triggered by chemoattractants such as vascular endothelial growth factor (VEGF) and sphingosine-1-phosphate (S1P). Because unchecked endothelial migration drives pathological vessel formation and inflammation, the negative regulation described by GO:2001027 is as important as the activating signals themselves. Mechanistically, negative regulation of endothelial chemotaxis can occur through receptor-proximal braking, cytoskeletal and Rho GTPase modulation, kinase inhibition and altered chemokine receptor trafficking. For example, S1P- and VEGF-induced endothelial chemotaxis are differentially regulated and involve G(ialpha2)-linked Rho kinase activity, showing that distinct chemoattractant pathways are subject to distinct negative control. Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity, providing a pharmacological example of negative regulation. For researchers, GO:2001027 provides a precise annotation target when studying anti-angiogenic strategies, vascular barrier protection and inflammatory disease. It also guides experimental design: assays must measure directionality and frequency of endothelial migration, not merely proliferation or survival, and must test whether a candidate gene causally reduces chemotaxis.
negative regulation of endothelial cell chemotaxis At A Glance
| GO ID | GO:2001027 |
|---|---|
| GO term | negative regulation of endothelial cell chemotaxis |
| Ontology | biological_process |
| Synonym | None listed |
| Major function | Dampening directed endothelial cell migration toward chemoattractants such as VEGF, S1P and FGF-2 |
| Representative triggers | VEGF, sphingosine-1-phosphate (S1P), FGF-2 and other chemoattractant gradients |
| Representative brakes | G(ialpha2)-linked Rho kinase pathways, Fes kinase downregulation and pharmacological tyrosine kinase inhibition |
| Disease relevance | Pathological angiogenesis, inflammatory barrier dysfunction and aberrant vascular remodeling |
| Research methods | Chemotaxis migration assays, phospho-signaling analysis, CRISPR knockout and overexpression models |
What Is GO:2001027?
In our own words, GO:2001027 (negative regulation of endothelial cell chemotaxis) refers to any biological process that stops, prevents or reduces the frequency, rate or extent of endothelial cell chemotaxis, meaning it dampens the directed movement of endothelial cells along a chemical gradient. It is a biological_process term in the Gene Ontology and has no listed synonyms in QuickGO.
Why Is negative regulation of endothelial cell chemotaxis Important in Cell Biology?
Negative regulation of endothelial cell chemotaxis is important because endothelial migration is a rate-limiting step in angiogenesis and vascular barrier remodeling, and loss of these braking mechanisms can promote pathological vessel growth or inflammatory leakage. Understanding GO:2001027 helps researchers interpret anti-angiogenic drug effects, design vascular biology experiments that distinguish chemotaxis from proliferation, and identify new therapeutic targets that selectively restrain endothelial movement without broadly killing endothelial cells.
• Controls the directionality and magnitude of endothelial cell migration during angiogenesis.
• Provides a mechanistic counterbalance to pro-angiogenic chemoattractants such as VEGF and S1P.
• Links pharmacological tyrosine kinase inhibition, such as gefitinib, to reduced endothelial chemotaxis via Fes downregulation.
• Relevant to inflammatory barrier function, where endothelial migration and permeability are tightly coupled.
• Helps explain why some anti-angiogenic strategies fail when negative regulation is bypassed.
• Guides CRISPR functional genomics screens for novel brakes on endothelial chemotaxis.
• Supports drug discovery by defining assays that measure chemotaxis rather than general cytotoxicity.
• Improves annotation of vascular single-cell and spatial transcriptomics datasets with a precise GO term.
What Happens During negative regulation of endothelial cell chemotaxis?
Sensing the chemoattractant gradient and initiating braking
In simple terms: Endothelial cells first read a chemical trail, and negative regulation starts when braking signals intercept that trail.
Endothelial chemotaxis begins when chemoattractants such as VEGF or sphingosine-1-phosphate (S1P) engage their receptors and establish a directional gradient. Negative regulation of this step can occur through differential control of S1P- versus VEGF-induced chemotaxis, which involves G(ialpha2)-linked Rho kinase activity, indicating that distinct chemoattractant inputs are subject to distinct inhibitory circuits. This means a cell can remain responsive to one attractant while its response to another is suppressed, a key feature of GO:2001027.
Receptor-proximal kinase braking
In simple terms: Kinases that relay the migration signal can be turned down, which slows the cell's movement.
Negative regulation can act at receptor-proximal kinases. Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity, demonstrating that reducing a specific kinase's activity can brake chemotaxis. This provides a concrete pharmacological example where a tyrosine kinase inhibitor reduces endothelial migration, and it supports the idea that kinase-dependent braking is a core mechanism within GO:2001027.
Cytoskeletal and Rho GTPase modulation
In simple terms: The cell's internal skeleton is reorganized so that it can no longer push forward efficiently.
Directed migration depends on Rho GTPase and Rho kinase signaling that reorganizes the actin cytoskeleton. Because G(ialpha2)-linked Rho kinase activity participates in differential regulation of S1P- and VEGF-induced endothelial chemotaxis, modulation of this axis is a plausible route for negative regulation. When this axis is dampened, endothelial cells lose the polarized protrusive activity needed for persistent chemotaxis, consistent with the definition of GO:2001027.
Chemokine receptor and trafficking control
In simple terms: The cell can reduce the number of receptors on its surface or change how they are recycled, making it less able to follow the signal.
Chemotaxis also depends on appropriate chemokine receptor availability and trafficking. Studies of CCRL2 regulation of leukocyte migration show that atypical chemokine receptors can shape migratory responses by controlling chemokine availability and receptor signaling. Although this work focuses on leukocytes, the principle that receptor-level control can dampen directed migration is relevant to negative regulation of endothelial chemotaxis and supports the broader concept of GO:2001027.
Integration with barrier and inflammatory signals
In simple terms: Inflammation and barrier signals can put the brakes on endothelial movement.
Endothelial chemotaxis is closely coupled to barrier function and inflammation. Nutri(epi)genomic analysis in healthy men showed that flavanol consumption preserves integrity of immunological-endothelial barrier cell functions, indicating that systemic and inflammatory cues can modulate endothelial behavior. Such cues may contribute to negative regulation of endothelial chemotaxis by shifting endothelial cells from a migratory to a barrier-stabilizing state, which is consistent with GO:2001027.
Key Genes Involved in GO:2001027 negative regulation of endothelial cell chemotaxis
The following genes and proteins have been experimentally linked to endothelial chemotaxis or its negative regulation and are useful entry points for studying GO:2001027.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Primary endothelial chemoattractant that drives chemotaxis | Used to stimulate chemotaxis in negative-regulation assays |
| S1PR1 | Receptor for sphingosine-1-phosphate mediating endothelial chemotaxis | Enables differential S1P versus VEGF chemotaxis experiments |
| GNAI2 | G(ialpha2) subunit linked to Rho kinase-dependent chemotaxis regulation | Tests G(ialpha2)-linked braking of endothelial migration |
| RHOA | Rho GTPase controlling cytoskeletal reorganization during migration | Candidate node for negative regulation of chemotaxis |
| ROCK1 | Rho kinase effector mediating actomyosin contractility | Pharmacological and genetic braking target |
| FES | Tyrosine kinase whose downregulation associates with reduced chemotaxis | Gefitinib-sensitive node for negative regulation |
| FGFR1 | Receptor for FGF-2 driving endothelial chemotaxis | Used to trigger chemotaxis in inhibition studies |
| EGFR | Receptor tyrosine kinase targeted by gefitinib | Upstream context for Fes-dependent braking |
| CCRL2 | Atypical chemokine receptor shaping directed migration | Model for receptor-level control of chemotaxis |
| ACKR2 | Atypical chemokine receptor family member | Conceptual template for chemokine scavenging and migration control |
| CCL2 | Chemokine influencing endothelial and leukocyte migration | Context for inflammatory modulation of chemotaxis |
| CCL5 | Chemokine involved in leukocyte recruitment and vascular inflammation | Comparator for chemokine-driven migration assays |
| STK40 | Serine/threonine kinase 40 targeted by microRNA-31 in inflammatory cytokine regulation | Example of kinase-linked inflammatory control relevant to endothelial signaling |
| MIR31 | MicroRNA-31 overexpressed in psoriasis, modulates cytokine and chemokine production | Model for non-coding RNA control of migratory signaling |
| FAK | Focal adhesion kinase involved in chemotaxis pathways | Candidate for adhesion-dependent braking of migration |
| PTK2 | Gene encoding FAK, a chemotaxis-associated kinase | CRISPR target for testing chemotaxis regulation |
| IL6 | Inflammatory cytokine influencing endothelial activation | Context for inflammation-linked negative regulation |
| TNF | Inflammatory cytokine modulating endothelial barrier and migration | Used to perturb barrier-chemotaxis coupling |
How Is negative regulation of endothelial cell chemotaxis Regulated?
Negative regulation of endothelial cell chemotaxis is itself regulated at multiple levels. Differential control of S1P- versus VEGF-induced chemotaxis involves G(ialpha2)-linked Rho kinase activity, meaning the same cell can brake one chemoattractant response while preserving another. Pharmacological inhibition of tyrosine kinase signaling, as seen with gefitinib and Fes downregulation, shows that receptor-proximal kinase activity is a tunable regulatory layer. Inflammatory and barrier-related signals, including those influenced by diet and immunological-endothelial barrier function, can also shift endothelial cells away from a migratory state. Together these layers allow context-specific braking of endothelial chemotaxis without permanently disabling the cell.
negative regulation of endothelial cell chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFA | Pathological angiogenesis and tumor vascularization | Endothelial chemotaxis assay with VEGF gradient and candidate brake knockout |
| FES | FGF-2-driven endothelial chemotaxis and drug response | Gefitinib-treated endothelial cells with FES knockdown or knockout |
| GNAI2 | Differential S1P versus VEGF chemotaxis regulation | GNAI2 knockout endothelial cells in S1P and VEGF gradients |
| CCRL2 | Chemokine-driven migration and inflammatory recruitment | CCRL2 loss- and gain-of-function migration models |
| MIR31 | Psoriasis-associated inflammatory cytokine and chemokine production | Keratinocyte-endothelial co-culture with miR-31 modulation |
Pathological angiogenesis and cancer
Endothelial chemotaxis is a rate-limiting step in angiogenesis, and loss of negative regulation can promote pathological vessel formation in tumors and ischemic tissues. Because VEGF and S1P drive endothelial migration through distinct pathways, therapeutic strategies that restore negative regulation may selectively restrain pathological angiogenesis. Pharmacological inhibition of chemotaxis toward FGF-2 by gefitinib, associated with Fes downregulation, illustrates how kinase-directed drugs can engage this process.
Inflammatory barrier dysfunction
Endothelial migration and barrier integrity are coupled, and inflammatory conditions can disrupt this balance. Nutri(epi)genomic analysis showed that flavanol consumption preserves immunological-endothelial barrier cell functions in healthy men, suggesting that systemic cues can modulate endothelial behavior relevant to negative regulation of chemotaxis. Inflammatory cytokines and chemokine networks, including atypical chemokine receptors such as CCRL2, further shape directed migration and may contribute to barrier dysfunction when braking fails.
Inflammatory skin and immune-mediated disease
MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40, showing that non-coding RNA and kinase networks can control chemokine output relevant to endothelial recruitment. Such mechanisms may indirectly influence negative regulation of endothelial chemotaxis by altering the chemokine environment.
From negative regulation of endothelial cell chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required to brake endothelial chemotaxis? | CRISPR knockout endothelial cell line or primary endothelial cells |
| Does a specific phosphorylation site control negative regulation? | Point-mutation knock-in of phospho-dead or phospho-mimetic residues |
| Does a disease-associated variant alter chemotaxis braking? | Knock-in of the patient variant with isogenic controls |
| Where does the candidate protein localize during chemotaxis? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a brake gene reduce migration? | Doxycycline-inducible overexpression endothelial model |
| Which genes are negative regulators at scale? | CRISPR library screening in a chemotaxis selection assay |
How to Study the negative regulation of endothelial cell chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Boyden chamber chemotaxis assay | Directional endothelial migration toward a chemoattractant | Testing VEGF, S1P or FGF-2-driven chemotaxis and its inhibition |
| Microfluidic gradient assay | Directionality and speed of migration in a stable gradient | Quantifying negative regulation of chemotaxis in real time |
| Phospho-kinase profiling | Activity of kinases such as Fes and Rho kinase | Identifying braking nodes after drug or gene perturbation |
| Single-cell RNA-seq | Endothelial cell states and migratory gene programs | Resolving migratory versus barrier-stabilizing populations |
| Nutri(epi)genomic profiling | Epigenetic and transcriptional responses to systemic cues | Linking diet or inflammation to endothelial barrier and migration |
| CRISPR library screening | Genes whose loss alters chemotaxis | Unbiased discovery of negative regulators |
| Immunofluorescence imaging | Cytoskeletal polarization and focal adhesion dynamics | Validating loss of directed migration machinery |
| Co-culture migration assays | Endothelial recruitment in an inflammatory context | Modeling chemokine-driven migration and its control |
Chemotaxis migration assays
The core readout for GO:2001027 is a directional migration assay, such as a Boyden chamber or microfluidic gradient device, in which endothelial cells migrate toward VEGF, S1P or FGF-2. Differential regulation of S1P- and VEGF-induced chemotaxis has been demonstrated using such assays, and inhibition of chemotaxis toward FGF-2 by gefitinib was measured in this way. Researchers should quantify directionality, speed and the frequency of migrating cells to distinguish chemotaxis from random motility.
Phospho-signaling and kinase profiling
Because negative regulation often acts through kinases, phospho-signaling readouts are essential. Fes activity downregulation associated with reduced chemotaxis toward FGF-2 illustrates how kinase profiling can identify braking nodes. Similarly, G(ialpha2)-linked Rho kinase activity in S1P- and VEGF-induced chemotaxis highlights the value of phospho-Rho kinase and related pathway measurements.
Transcriptomic and proteomic profiling
Bulk and single-cell transcriptomics can reveal shifts between migratory and barrier-stabilizing endothelial states. Characterization of muscle tissue cell diversity in idiopathic inflammatory myopathy demonstrates how single-cell approaches resolve cell states in inflammatory tissue. Nutri(epi)genomic analysis further shows that systemic exposures can alter endothelial barrier and immunological functions, which can be monitored by transcriptomic and epigenetic profiling.
CRISPR functional genomics
CRISPR knockout and library screening allow unbiased discovery of negative regulators of endothelial chemotaxis. By combining chemotaxis selection with sgRNA libraries, researchers can identify genes whose loss increases migration, directly annotating GO:2001027. Candidate hits can then be validated with point-mutation, knock-in or overexpression models to establish causality.
How CRISPR Can Be Used to Study GO:2001027 negative regulation of endothelial cell chemotaxis
Knockout
CRISPR knockout of candidate genes such as GNAI2, RHOA, ROCK1 or FES in endothelial cells allows direct testing of whether the gene is required for negative regulation of chemotaxis. Loss of a true brake is expected to increase migration toward VEGF, S1P or FGF-2, providing a causal readout for GO:2001027.
Point Mutation
Point-mutation models can dissect specific phosphorylation or catalytic residues within kinases and GTPases that control chemotaxis. For example, mutating residues that regulate Rho kinase or Fes activity can reveal whether a single phospho-site is necessary for braking endothelial migration. Such models are valuable when complete knockout causes lethality or confounding developmental effects.
Knock-in
Knock-in of disease-associated variants or tagged alleles enables allele-specific studies of negative regulation of endothelial chemotaxis. Tagged knock-in of candidate proteins allows localization and interaction studies during gradient sensing, while variant knock-in can test whether a patient mutation impairs braking. Isogenic controls are essential to attribute phenotypes to the variant rather than background.
Overexpression
Overexpression of a candidate brake gene, often under an inducible promoter, tests sufficiency: if the gene reduces endothelial chemotaxis when overexpressed, it is a strong candidate for GO:2001027. Inducible systems help avoid adaptation and allow dose-dependent analysis of braking strength.
How EDITGENE Supports negative regulation of endothelial cell chemotaxis Research
Researchers studying negative regulation of endothelial cell chemotaxis-related genes often need to determine whether a candidate gene is causally involved in braking endothelial migration or is merely correlated with a migratory phenotype. This requires clean genetic models in which the candidate gene is removed, mutated, tagged or overexpressed in endothelial cells, combined with quantitative chemotaxis assays and signaling readouts.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of endothelial cell chemotaxis research.
Frequently Asked Questions About negative regulation of endothelial cell chemotaxis
What is GO:2001027 negative regulation of endothelial cell chemotaxis?
GO:2001027 is a Gene Ontology biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell chemotaxis, the directed migration of endothelial cells along a chemical gradient.
What genes are involved in negative regulation of endothelial cell chemotaxis?
Genes and proteins implicated include GNAI2, RHOA, ROCK1 and FES, based on studies of G(ialpha2)-linked Rho kinase activity and Fes downregulation during endothelial chemotaxis.
How is endothelial cell chemotaxis negatively regulated?
Negative regulation can occur through receptor-proximal kinase braking, Rho GTPase and cytoskeletal modulation, and altered chemokine receptor trafficking, as shown by differential S1P versus VEGF regulation and gefitinib-associated Fes downregulation.
Which chemoattractants drive endothelial cell chemotaxis?
VEGF, sphingosine-1-phosphate (S1P) and FGF-2 are well-established chemoattractants used to trigger endothelial chemotaxis in experimental systems.
Why is negative regulation of endothelial chemotaxis important in cancer?
Because endothelial chemotaxis is rate-limiting for angiogenesis, loss of braking mechanisms can promote pathological vessel formation in tumors, making this process a therapeutic target.
What assays measure negative regulation of endothelial cell chemotaxis?
Boyden chamber and microfluidic gradient assays quantify directional endothelial migration, while phospho-kinase profiling identifies braking nodes such as Fes and Rho kinase.
Can CRISPR be used to study GO:2001027?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of candidate genes, and CRISPR library screening can discover new negative regulators of endothelial chemotaxis.
How does gefitinib affect endothelial cell chemotaxis?
Gefitinib inhibits endothelial cell chemotaxis toward FGF-2, and this inhibition associates with downregulation of Fes activity.
What is the difference between S1P- and VEGF-induced endothelial chemotaxis?
S1P- and VEGF-induced endothelial chemotaxis are differentially regulated and involve G(ialpha2)-linked Rho kinase activity, indicating distinct negative control mechanisms for each chemoattractant.
Which diseases involve dysregulated endothelial chemotaxis?
Pathological angiogenesis, inflammatory barrier dysfunction and immune-mediated inflammatory conditions such as psoriasis have been linked to altered endothelial and chemokine-driven migration.
Conclusion
GO:2001027, negative regulation of endothelial cell chemotaxis, defines the braking mechanisms that restrain directed endothelial migration toward chemoattractants such as VEGF, S1P and FGF-2. Experimental evidence implicates G(ialpha2)-linked Rho kinase activity and Fes kinase downregulation as key nodes, and pharmacological inhibition with gefitinib provides a concrete example of chemotaxis braking. Because endothelial chemotaxis is central to angiogenesis and barrier function, this term is highly relevant to cancer, inflammation and vascular disease research. Studying GO:2001027 requires quantitative chemotaxis assays combined with causal genetic models. CRISPR knockout, point-mutation, knock-in and overexpression approaches, together with CRISPR library screening and bioinformatics, allow researchers to move from correlation to causation and to identify new therapeutic brakes on endothelial migration.
References
- 2. Delecluse S et al.. 2025. Epstein-Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways.. Nat Commun 16(1):4581 PMID: 40389409
- 3. Zhu H et al.. 2025. Characterization of Muscle Tissue Cell Diversity and Clinical Implications in Idiopathic Inflammatory Myopathy.. J Cachexia Sarcopenia Muscle 16(5):e70043 PMID: 40874258
- 4. Liu F et al.. 2001. Differential regulation of sphingosine-1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity.. Am J Respir Cell Mol Biol 24(6):711-9 PMID: 11415936
- 5. Milenkovic D et al.. 2022. Flavanol Consumption in Healthy Men Preserves Integrity of Immunological-Endothelial Barrier Cell Functions: Nutri(epi)genomic Analysis.. Mol Nutr Food Res 66(21):e2100991 PMID: 35094491
- 6. Xu N et al.. 2013. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40.. J Immunol 190(2):678-88 PMID: 23233723
- 7. Schioppa T et al.. 2020. Molecular Basis for CCRL2 Regulation of Leukocyte Migration.. Front Cell Dev Biol 8:615031 PMID: 33363177
- 8. Kanda S et al.. 2009. Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity.. Int J Oncol 35(6):1305-12 PMID: 19885553
